About this trial
Sevoflurane is one of the most commonly used volatile anesthetics in children because of its rapid induction, recovery and recovery properties. Clinical studies using noninvasive brain monitoring have shown that general anesthetics and hypnotics generate electroencephalogram (EEG) oscillations in specific spatial tissues that are fundamentally related to the structure and function of neural circuits. Slow-wave-delta (0.1-4 Hz) oscillations were present in children of all ages, and the advantage of frontal α-wave oscillations appeared at approximately 6 months, began to be consistent at 10 months, and persisted at older ages. Another study, which analyzed EEG under sevoflurane general anesthesia in children aged 0-6 months, found that Theta and alpha wave power decreased with a decrease in sevoflurane concentrations in infants between 4 and 6 months of recovery. However, these studies lack detailed characterization of the neural circuit activity associated with anesthesia, especially at specific developmental ages that are highly correlated with brain plasticity. The aim of this study was to explore electroencephalogram (EEG) of children of different ages under sevoflurane general anesthesia (including anesthesia induction, maintenance and recovery) . By analyzing these EEG data in detail, we hope to be able to better understand the EEG characteristics of children of different ages under sevoflurane anesthesia, and thus develop a neurophysiology pediatric anesthesia status monitoring strategy.
Eligibility criteria
Qualifiers
aged 1 days#6 years#;
with American Society of Anesthesiologists (ASA) physical status I or II#;
children requiring general anesthesia under sevoflurane;
parents or legal guardians of children who volunteered to participate in the trial; And signed the informed consent form.
Disqualifiers
Congenital malformation or other genetic conditions that are thought to affect brain development ;
History of severe heart, brain, liver, kidney and metabolic diseases ;
Premature infants (≤32 weeks);
Upper respiratory tract infection in the last two weeks.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
14
Trial groupsSee each trial group below.